# Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis

> **NCT02015520** · PHASE2 · COMPLETED · sponsor: **CSL Behring** · enrollment: 143 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Clazakizumab
- **DRUG:** Placebo (Matching with Clazakizumab)

## Key facts

- **NCT ID:** NCT02015520
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2013-06
- **Final completion:** 2015-06
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2021-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02015520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02015520, "Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02015520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*